Considering that current therapies to alleviate PD symptoms and progression are based on the administration of dopamine precursor L-Dopa and/or dopamine D2 receptor agonists (Oertel and Schulz, 2016), the understanding of Cav1.3 physiology becomes crucial to better define the pathways involved in PD onset and develop therapeutic strategies. The gene discussed is CACNA1D; the disease is Parkinson disease.